Top Research Papers on Heterocyclic Compounds PDF

Heterocyclic compounds represented by the general formula (I): (I) wherein X and Y are different from each other and are halo selected from among chloro, bromo and iodo, CF3SO3-, CH3SO3-, C6H5SO3-, or CH3C6H4SO3-; R1 is an optionally substituted monovalent aliphatic hydrocarbon group having two or more carbon atoms; one of A1 and A2 is-S-,-O-,-Se-or-Te-, while the other is-N=,-P=, or-Si(R2)= (wherein R2 is hydrogen, an optionally substituted monovalent hydrocarbon group, halogen, amino or carbonyl); and one of the two linkages each represented by a solid line and a broken line is a single bond...

公开了一种由式1A表示的杂环化合物和一种包括该杂环化合物的有机发光装置：式1AR1至R13中的至少一个是由下面的式1B表示的基团：式1B其中，R1至R15、Ar1、Ar2、A、B、a和b如说明书中所定义。 该有机发光装置可包括包含该杂环化合物的有机层，因此可具有低驱动电压、高发射效率和长寿命特性。

In particular there is provided a compound of formula (I) as defined in the present specification p38 MAP kinase inhibitors for use as a medicament for the treatment of inflammatory diseases.

A selected from Formula 1 or Formula 1A compound, its N-oxides and salts, ** ** Formula wherein E is ** ** Formula Y1, Y2 and Y3 in formula 1 form a ring selected from ** ** formula wherein the bond projecting to the left, marked with a * in L-1, L-2 and L-9 is attached to E in formula 1 and the bond projecting to the right, marked with a T, it is connected to G in Formula 1; Y2, X1 and X2 in Formula 1A form a ring selected from ** ** Formula wherein the bond projecting to the left, marked with a * in L-60 and L-64, is attached to E in Formula 1A and the bond projecting to the right, marked wi...

The present invention provides pharmaceutical compositions comprising compounds of Formula I and methods of treating or preventing one or more conditions that may be regulated or normalized via inhibition of dipeptidyl peptidase IV (DPP-IV).

The compound is useful as a medicinal ingredient having a CRF antagonistic activity for use in the prevention and/or treatment of a neurological/psychiatric disease, a disease in a terminal organ or the like.

Proposed compounds are inhibitors of calcium channel function being especially inhibitor of K v 1 subfamily of potential-overlapping K + -channels and especially inhibitors ofK v 1.5 that associated with super-rapid activating delayed cleaning K +-flow of I kur and can be used in treatment of arrhythmia and IKur -associated diseases.

The present invention provides a compound with the unexpected insecticidal activity. A compound of formula (I): [Formula 1] Preferred compounds are, How to spraying the compounds of formula (I), the composition consisting of optionally the second compound and the carrier and this if you are a pest.

New heterocyclic compounds of the formula (I) (wherein, R 1, D, W, T, and T has the meanings indicated in claim 1) is a SGK inhibitors, SGK may be used for the treatment of induced diseases and conditions.

(57) Abstract: The present invention relates to a process for the production of intermediates useful for preparing the therapeutically active azacyclic or aza bicyclic compounds.

A useful antidepressant compound showing inhibition of 5-HT reuptake is provided, and its application in clinical practice is still under investigation.

Compounds of the present invention as depression, schizophrenia, Alzheimer's disease or attention deficit hyperactivity disorder (ADHD) and other drugs useful for the prophylaxis or treatment.

The patent application relates to new heterocyclic compounds of the general formula (I), in which R, R1, R2, Q, T, n and p have the definitions elucidated in more detail in the description, to a process for preparing them and to the use of these compounds as medicaments, particularly as aldosterone synthase inhibitors.

The present invention provides a PDE9 inhibitor compound of formula (I) and pharmaceutically acceptable salts thereof and pharmaceutical compositions containing compounds of formula I and their use in the treatment of neurodegenerative and cognitive disorders such as Alzheimer's disease and schizophrenia.

A compound represented by the formula (I) or a salt of the compound is a tyrosinkinase inhibitor or a preventive/therapeutic agent for cancers which each contains the compound or a prodrug thereof.

All that are described are novel heterocyclic compounds of general formulae and (values of radicals are given in invention formula), pharmaceutical compositions containing them and application of said heterocyClic compounds for treatment disorders mediated with MAP kinase cascade.

PURPOSE: To obtain a new nitrogen heterocyclic compd. effective in treating hypertension, congestive heart failure, etc. CONSTITUTION: The nitrogen heterocyclic compd. is a compd. of formula I [where R 1 is H, alkyl, phenyl, etc.; R 2 is H, alkyl or cycloalkyl; R 3 is R 1 , a halogen, alkoxy, amino, etc.; R 4 is H, amino, OH, alkoxy, alkyl, carboxy, CN, NO 2 , phenyl, etc.; R 5 is H; R 6 is H or alkyl; R 7 is H, alkyl, alkoxy, halogen, CN, etc.; X is phenylene or a direct bond; Rz is H, alkyl, alkanoyl or benzoyl; and Z is 1H-tetrazol-5-yl, COOR 8 (R 8 is H, the residue of a physiologically ac...

THE INVENTION RELATES TO THE PREPARATION OF HETEROCYCLIC COMPOUNDS. IT RELATES TO A METHOD OF PREPARATION OF A COMPOUND OF THE GENERAL FORMULA (CF DRAWING IN BOPI) R REPRESENTS OR ATOM HYDROGEN OR GROUP MAY BE sUBSTITUTED alkyl or cycloalkyl, R REPRESENTS A GROUP MAY BE sUBSTITUTED alkyl or cycloalkyl, R EACH AND REGARDLESS R REPRESENTS A GROUP alkyl or cycloalkyl MAY SUBSTITUTE AND EACH R AND R REPRESENTS INDEPENDENT GROUP alkyl, cycloalkyl, alkenyl, alkynyl, aRYL OR optionally substituted aralkyl, INCLUDING THE REACTION OF hYDRAZONE APPROPRIATE WITH A SUITABLE DICARBOXYLATE. PRODUCTS ARE USE...

The present invention is also a process for preparing the compounds described above, and pharmaceutical compositions containing them, as well as to the use of these.

The compounds of the present invention is useful for diseases such as chronic obstructive pulmonary disease, cancer or the treatment and / or prevention of skin disorders.

All geometric and stereoisomers, tautomers, and the compounds of formula 1 is disclosed containing the N- oxides and salts, [Formula 1] In the formula, E, X, Y, G, Z and Q are as defined in the present disclosure. The compositions containing the compounds of formula 1, and, a method for controlling plant diseases caused by fungal pathogens comprising applying an effective amount of a compound or composition of the present invention is disclosed.

The present invention provides compounds of formula (I) and salts thereof, wherein Ring A is an optionally substituted 5 to 10 membered aromatic ring; R

A review of the literature on the synthesis of heterocycles revealed several that produced significant yields and could be modified for the organic laboratory.

本発明は、一般式（Ｉ）（式中、ＤおよびＧは、置換基を有していてもよい環状基、または置換基を有していてもよいアルキル基を表わし、ＷおよびＹは、結合手または主鎖の原子数１〜４のスペーサーを表わし、環Ａおよび環Ｂは、少なくとも１個の炭素原子および少なくとも１個の窒素原子を含有してなる、置換基を有していてもよい複素環を表わし、環Ａと環Ｂは１個のスピロ炭素原子を共有する。）で示される化合物、その塩、そのＮ−オキシド体、それらの溶媒和物、またはそれらのプロドラッグに関する。 一般式（Ｉ）で示される化合物はＭＢＲに親和性を有するため、ストレスに起因する疾患の予防および／または治療薬として有用である。

PURPOSE: To provide a new sulfinylation process of a heterocyclic compound wherein the difficulty of oxidation and the toxicity of reactants are avoided. CONSTITUTION: A compound of the formula: RS(O)X [wherein R is a 1-4C, linear or branched alkyl substituted by one or more halogens; and X is a halogen, OH, NR 2 R 3 (wherein R 2 and R 3 are each a 1-4C alkyl or 1-4C haloalkyl) or aryloxy (wherein the aryl portion is preferably phenyl which is optionally substituted by one or more halogens, 1-4C alkyl or 1-4C haloalkyl)] is allowed to react with a heterocyclic compound chosen from the group co...

The present invention includes a method which comprises administering an effective amount of a compound (I) for the required certain mammals.

A fused heterocyclic compound having an enteropeptidase inhibitory action and use of the compound as a medicament for treatment or prophylaxis of obesity, diabetes mellitus, etc., are provided.

The configuration of the present invention is a compound of formula (I), its salts and solvates thereof, in the preparation of these compounds, pharmaceutical formulations containing these compounds and their use in medicine, particularly in the treatment of migraine applications. Structural formula (I) above.

The present application provides compounds of formula (I) that modulate the activity of stearoyl-CoA desaturase and pharmaceutical compositions comprising such derivatives.

A compound having the general formula (I), or a pharmacologically acceptable salt thereof, wherein each substituent has the following values: r and R, each optionally predstavlyayutatom hydrogen or a group selected from Substituent group α, or together form a substituents having regard for two provisions.

Methods for the synthesis of heterocyclic compounds including N-(3,5~dichloropyrid-4-yl)-4- difluoromethoxy-8-methanesulfonamido-dibenzo[b,d]furan-l-carboxamide and pharmaceutically acceptable salts thereof.

Main aim of this paper is to present the information regarding the Heterocyclic compounds that constitute the largest family of organic compounds. These are extremely important with wide array of synthetic, pharmaceutical and industrial applications. There is always a strong need for new and efficient processes in synthesizing of new Heterocycles. Several 1,3,4,5-tetraaryl-2 pyrazoline, 41 -piperazine, 3- methoxybenzofuran and thiazolidin-4-one substituted 1, 2, 4-triazole, 4- NO2, 2-OH and 4-Cl in phenyl ring at 5- position of pyrazoline ring of synthesized compounds. The new compounds were c...

The IUPAC Gold Book describes heterocyclic compounds as: “Cyclic compounds having as ring members atoms of at least two different elements, e.g. quinoline, 1,2-thiazole, bicyclo[3.3.1]tetrasiloxane” [1]. Usually they are indicated as counterparts of carbocyclic compounds, which have only ring atoms from the same element. Another classical reference book, the Encyclopaedia Britannica, describes a heterocyclic compound, also called a heterocycle, as: “Any of a class of organic compounds whose molecules contain one or more rings of atoms with at least one atom (the heteroatom) being an element ot...

The present invention relates to spiro compounds having electron-conducting groups and to electronic devices, in particular organic electroluminescent devices, containing said compounds.

1 Three-Membered Perfluorohalogenoorgano Nitrogen Heterocycles.- 2 Four-Membered Perfluorohalogenoorgano Nitrogen Heterocycles.- 3 Five-Membered Perfluorohalogenoorgano Nitrogen Heterocycles.- 4 Six-Membered Perfluorohalogenoorgano Nitrogen Heterocycles.- 5 Perfluorohalogenoorgano Nitrogen Heterocycles with More than Six Atoms in the Ring.- 6 Fused Perfluorohalogenoorgano Nitrogen Heterocycles.- Formula Index.- Table of Conversion Factors.

, (II) compounds and their prodrugs represented by wherein each symbol is as defined in the description of Formula (the I), having an excellent renin inhibitory activity and useful as hypertension, various organ damages caused by hypertension and the like of preventive or therapeutic agents.

The present invention relates to novel N- substituted Azahetero cyclic carboxylic acids and their esters or their salts substituted alkyl chain forms part of the N- substituent to a process for their preparation, their the composition comprising, and a ecological pathological role pain by C fibers induces neurogenic pain or inflammation, hyperalgesia, and / or their use for the clinical treatment of inflammatory conditions on.

Disclosed are: a heterocyclic derivative which has excellent amyloid ss production inhibitory activity,and a use of the heterocyclic derivative. Specifically disclosed is a compound represented by formula (I) (wherein the symbols are as defined in the description), or a salt thereof.

The present invention discloses heterocyclic pyrimidine compounds which selectively adjusting mutant epidermal growth factor receptor EGFR kinase activity and a variety of selective inhibition of EGFR mutations.

A fused heterocyclic compound used as a platelets aggregation inhibitor is provided to prevent thrombokinesis with broad activity of suppressing platelet aggregation.

Compound (I), or relates to a pharmaceutically acceptable salt thereof to interferon inducing agent, a therapeutic agent of the antibacterial agents, anticancer agents and immunogenic diseases containing as an active ingredient.

The present invention relates to novel N-substituted azaheterocyclic carboxylic acids and esters thereof to methods for their preparation, to compositions containing them, and to their use for the clinical treatment of painful, hyperalgesic and/or inflammatory conditions in which C-fibers play a pathophysiological role by eliciting neurogenic pain or inflammation.

N-Alpha-halopropionyl-heterocyclic cpds. of formula (I) are new, where R1-R4 = H, 1-8C alkyl, aryl-(1-8C)alkyl or aryl; or R1+R2 and/or R3+R4 = 1-8C alkylene; or R1+R2+R3+R4 = residue of o-phenylene; X = halogen; Y = O or N substd. by 1-8C alkyl or aryl. Beta-lactam derivs. of formula (II) where R = H or protecting gp.. Pref. in (I) and (II), R1 = R2 = Me; R3 = R4 = H; Y = O.

本発明は、スキーム１に示す式Ｉの複素環化合物を合成する方法に関する。 上記の方法によれば、式IIのイソチオシアン酸エステルと式IIIの第一級アミンを反応させて式IVのチオ尿素を得る。 次いで、式IVのチオ尿素を塩基及びスルホン酸を用いて式Ｉの複素環に変換する。 【化１】

The purpose is to obtain a new substd.

FIELD: chemistry. SUBSTANCE: invention relates to novel compounds of formula (I) or pharmaceutically acceptable salts thereof, having CRP receptor antagonist activity. In formula (I) R 1 denotes C 3 -C 8 alkyl, optionally substituted with hydroxyl; phenyl optionally substituted with 1-3 substitutes selected from halogen, nitro, amino, hydroxyl, C 1 -C 4 alkoxy, C 1 -C 4 alkyl, optionally substituted with hydroxyl or C 1 -C 4 alkylamino; naphthyl; C-bonded 5-6-member heteroaryl with 1-2 heteroatoms selected from S, N or O, optionally substituted with C 1 -C 4 alkyl, C 1 -C 4 alkoxy or acetyl; N...

the chemistry of heterocyclic compounds are a good way to achieve details about operating certainproducts. Many products that you buy can be obtained using instruction manuals. These user guides are clearlybuilt to give step-by-step information about how you ought to go ahead in operating certain equipments. Ahandbook is really a user's guide to operating the equipments. Should you loose your best guide or even the productwould not provide an instructions, you can easily obtain one on the net. You can search for the manual of yourchoice online. Here, it is possible to work with google to brows...

It REFERS TO COMPOUNDS ethenyl-1,3-oxazole-4-METHOXY of formula I, wherein n is 1-2; R1 is halogenated C1-C2 optionally halogen; One of R2 and R3 is H, the other is a group a, b; n is 3-4; R4 is C1-C4 substituted with OH. Preferred compounds 1-4- {4 - [(2 - {(E) -2- [4- (trifluoromethyl) phenyl] ethenyl} -1,3-oxazol-4-yl) methoxy] phenyl} butyl) -1H -1,2,3-triazole; 1- (3- {3 - [(2 - {(E) -2- [4- (trifluoromethyl) phenyl] ethenyl} -1,3-oxazole-4-yl) methoxy] phenyl) propyl) -1H-1 , 2,3-triazole; 3-1- {4- [4 - ({2 - [(E) -2- (2,4-difluorophenyl) ethenyl] -1,3-oxazole-4-yl} methoxy) phenyl] buty...

(57) Abstract: The present invention provides a useful heterocyclic compounds in the regulation of muscarinic receptors.

The present invention, various disease states, especially cardiovascular diseases, treatment effective for, provides novel heterocyclic derivative that is also effective in the treatment of diabetes mellitus.